Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Jennifer Zlott"'
Autor:
Jan H. Beumer, Benjamin C. Kennard, Julianne L. Holleran, Nancy Moore, Jennifer Zlott, Brian M. Miller, Shivaani Kummar, Alice Chen, James Doroshow, Wansu Park, Jogarao Gobburu, Allison Dunn
Publikováno v:
Cancer Chemotherapy and Pharmacology. 91:219-230
Autor:
Alice P. Chen, James H. Doroshow, Ganesh Mugundu, Biswajit Das, Ting-Chia Chang, Li Chen, Ralph E. Parchment, Robert J. Kinders, Deborah Wilsker, Jiuping Ji, Sarah B. Miller, Arjun Mittra, Howard Streicher, Elad Sharon, Richard Piekarz, Larry Rubinstein, Jennifer Zlott, Lamin Juwara, Ashley Bruns, Khanh Do, Shivaani Kummar, Geraldine O'Sullivan Coyne, Abdul Rafeh Naqash, Naoko Takebe
Purpose:The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c8ae5c4e40d695b8ef0f809480cf004
https://doi.org/10.1158/1078-0432.c.6530684.v1
https://doi.org/10.1158/1078-0432.c.6530684.v1
Autor:
Alice P. Chen, James H. Doroshow, Ganesh Mugundu, Biswajit Das, Ting-Chia Chang, Li Chen, Ralph E. Parchment, Robert J. Kinders, Deborah Wilsker, Jiuping Ji, Sarah B. Miller, Arjun Mittra, Howard Streicher, Elad Sharon, Richard Piekarz, Larry Rubinstein, Jennifer Zlott, Lamin Juwara, Ashley Bruns, Khanh Do, Shivaani Kummar, Geraldine O'Sullivan Coyne, Abdul Rafeh Naqash, Naoko Takebe
Supplementary Methods, Supplementary Fig. S1 (Mean adavosertib plasma concentrations for QD vs. BID schedules), Supplementary Fig. S2 (Example PD biomarker immunofluorescence images), Supplementary Fig. S3 (CCNE1 tumor alteration frequency IMPACT dat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47a74ee9d08ad2a06e7e92b80d4c2a9a
https://doi.org/10.1158/1078-0432.22481402
https://doi.org/10.1158/1078-0432.22481402
Autor:
Alice P. Chen, James H. Doroshow, John J. Wright, Rene Costello, Donald Bottaro, Andrea Regier Voth, Naoko Takebe, Elad Sharon, Howard Streicher, Richard Piekarz, Robert Meehan, Lamin Juwara, Jared C. Foster, Lawrence Rubinstein, Ashley Bruns, Jennifer Zlott, Khanh T. Do, Warren A. Chow, Kristen Ganjoo, James Hu, Shivaani Kummar, Geraldine O'Sullivan Coyne
Supplementary Data from Clinical Activity of Single-Agent Cabozantinib (XL184), a Multi-receptor Tyrosine Kinase Inhibitor, in Patients with Refractory Soft-Tissue Sarcomas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18093bd7818563307195df58214a4506
https://doi.org/10.1158/1078-0432.22483926
https://doi.org/10.1158/1078-0432.22483926
Autor:
Alice P. Chen, James H. Doroshow, John J. Wright, Rene Costello, Donald Bottaro, Andrea Regier Voth, Naoko Takebe, Elad Sharon, Howard Streicher, Richard Piekarz, Robert Meehan, Lamin Juwara, Jared C. Foster, Lawrence Rubinstein, Ashley Bruns, Jennifer Zlott, Khanh T. Do, Warren A. Chow, Kristen Ganjoo, James Hu, Shivaani Kummar, Geraldine O'Sullivan Coyne
Purpose:Soft-tissue sarcomas (STS) are a rare, heterogeneous group of mesenchymal tumors. For decades the mainstay of treatment for advanced, unresectable STS has been palliative chemotherapy. High levels of activated MET receptor have been reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acae07441313ff191c17c7376293dd3a
https://doi.org/10.1158/1078-0432.c.6531276.v1
https://doi.org/10.1158/1078-0432.c.6531276.v1
Autor:
Robert S. Meehan, Ashley Bruns, Lamin Jawara, Geraldine O'Sullivan Coyne, James C. Hu, Naoko Takebe, Alice P. Chen, S. Kummar, Andrea Regier Voth, Jared C. Foster, Howard Streicher, Kristen N. Ganjoo, Khanh T. Do, Rene Costello, Elad Sharon, Jennifer Zlott, Larry Rubinstein, Donald P. Bottaro, Warren A. Chow, John Wright, Richard Piekarz, James H. Doroshow
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 28, iss 2
Clin Cancer Res
Clin Cancer Res
Purpose: Soft-tissue sarcomas (STS) are a rare, heterogeneous group of mesenchymal tumors. For decades the mainstay of treatment for advanced, unresectable STS has been palliative chemotherapy. High levels of activated MET receptor have been reported
Autor:
Kazusa Ishii, Robert S. Meehan, Peter W. Laird, Jay N. Lozier, Larry D. Anderson, Angie B. Dull, Richard Piekarz, Andrea Regier Voth, Toshinori Hinoue, Jerry M. Collins, Katherine V. Ferry-Galow, James H. Doroshow, Elad Sharon, Howard Streicher, Khanh T. Do, Shivaani Kummar, Geraldine O.Sullivan Coyne, Naoko Takebe, Robert J. Kinders, Deborah Wilsker, Larry Rubinstein, Alice P. Chen, Jennifer Zlott, Ralph E. Parchment, Lamin Juwara
Publikováno v:
Oncotarget
Background TRC102 inhibits base excision repair by binding abasic sites and preventing AP endonuclease processing; it potentiates the activity of alkylating agents, including temozolomide, in murine models. In published xenograft studies, TRC102 enha
Autor:
James H. Doroshow, Ting-Chia Chang, Sarah B. Miller, Jennifer Zlott, Lamin Juwara, Li Chen, Abdul Rafeh Naqash, Khanh T. Do, Geraldine O'Sullivan Coyne, Elad Sharon, Deborah Wilsker, Jiuping Ji, Alice P. Chen, Biswajit Das, Shivaani Kummar, Ashley Bruns, Larry Rubinstein, Ganesh Mugundu, Richard Piekarz, Arjun Mittra, Robert J. Kinders, Naoko Takebe, Howard Streicher, Ralph E. Parchment
Publikováno v:
Clin Cancer Res
Purpose: The Wee1 kinase inhibitor adavosertib abrogates cell-cycle arrest, leading to cell death. Prior testing of twice-daily adavosertib in patients with advanced solid tumors determined the recommended phase II dose (RPh2D). Here, we report resul
Autor:
Geraldine O.Sullivan Coyne, Seth M. Steinberg, Richard Piekarz, Sarah B. Miller, S. Koehler, Lihua Wang, Jorge Nieva, David R. Gandara, Agustin A. Garcia, James H. Doroshow, Edward M. Newman, Alice P. Chen, Jan H. Beumer, Larry Rubinstein, Jennifer Zlott, Ralph E. Parchment, Mihaela C. Cristea, Joseph M. Covey, Shivaani Kummar, Lamin Juwara, Sonny Khin, Robert J. Kinders, Brandon Miller
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Following promising responses to the DNA methyltransferase (DNMT) inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) combined with tetrahydrouridine (THU) in phase 1 testing, we initiated a non-randomized phase 2 study to assess response to this c
Autor:
Mohamad A. Salkeni, Geraldine O’Sullivan Coyne, Jennifer Zlott, Naoko Takebe, Ning Ma, Larry Rubinstein, Richard Piekarz, Jared Foster, Brandon Miller, Ralph Parchment, Abdul R. Naqash, Andrea Voth, James Doroshow, Alice Chen
Publikováno v:
Molecular Cancer Therapeutics. 20:P049-P049
Background: TRC102 binds to abasic sites in DNA, inhibiting the base excision repair (BER) pathway, which is implicated in resistance to alkylating agents. Preclinical xenograft studies in mice demonstrated a synergistic anti-tumor effect when TRC102